VanEck Vectors Biotech ETF

NASDAQ: BBH
$131.68
-$1.87 (-1.4%)
Closing price April 7, 2020
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
Chris Lange
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.
Lee Jackson
Source: Jon OggBiotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many investors, what investors need...
Jon C. Ogg
Source: Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to get...
Jon C. Ogg
Source: Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the...
Jon C. Ogg
Index changes are generally speaking a fairly routine event.  They can also create underlying moves in the companies added and deleted from them as money management firms often buy and sell shares,...
Jon C. Ogg
We have compiled a detailed list of expected upside in the biotech sector.  The sector has consolidated and now there is about to be a rush of earnings reports from tomorrow’s emerging drug...
Jon C. Ogg
Biotech is becoming the ever-shrinking stock sector.  It is almost weekly now that a new biotech acquisition is announced.  Big Pharma in the United States and large drugmakers internationally...
Jon C. Ogg
The proposed buyout of Genzyme Corporation (NASDAQ: GENZ) by Sanofi-Aventis (NYSE: SNY) should close this week.  We are about to get a new Genzyme security on the market and that will be the...
Jon C. Ogg
Futurists are an odd lot.  Generally, they are authors, scientists,  consultants and economists.  What many people don’t know is that investors follow this philosophy as well.  Their goal is to...
Douglas A. McIntyre
Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally.  It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful...
Jon C. Ogg
Today’s version of the BioHealth Business Daily is rather different as we have a big disappointment from one of the top biotech operations in the world.  BioHealth stocks moving on news and after...
Jon C. Ogg
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
Douglas A. McIntyre
Biotech’s are sliding along with all the others today. A look at the highlights and outliers: Amgen (NASDAQ: AMGN) and Wyeth (NYSE: WYE) announced that arthritis and psoriasis drug Enbrel will now...
Douglas A. McIntyre
Genentech (NYSE: DNA) is set to report earnings after the close today.  First Call has estimates pegged at $0.67 EPS on revenues of $2.97 Billion.  This will also mark the end of the fiscal...
Douglas A. McIntyre